Pfizer (NYSE: PFE) increased the lower end of its full-year revenue forecast after second-quarter sales rose 3%, with growth from Eliquis, Padcev and other non-Covid medicines offsetting weaker demand for its Covid products.
The company reported quarterly revenue of $15.03 billion, compared with the $14.41 billion expected by analysts surveyed by LSEG. Adjusted earnings were 77 cents per share, exceeding the consensus estimate of 68 cents. Eliquis generated $2.43 billion in sales during the quarter, up 19% from the prior-year period. StreetAccount analysts had projected $2.08 billion in revenue from the blood thinner. Pfizer also identified the cancer medicine Padcev as a contributor to product growth.
Despite the increase in revenue, Pfizer recorded a net loss of $248 million, or 4 cents per share. A year earlier, the company reported net income of $2.91 billion, or 51 cents per share.
The loss included $4.3 billion in non-cash impairment charges related to intangible assets. After excluding certain items, including restructuring expenses and intangible asset costs, Pfizer earned an adjusted 77 cents per share.Pfizer now projects full-year revenue of $60.5 billion to $62.5 billion. Its previous forecast called for sales of $59.5 billion to $62.5 billion.
The company said the higher lower bound reflects an anticipated $1.5 billion increase in sales from products outside its Covid portfolio. The revised range would place annual revenue roughly even with or slightly below the $62.6 billion reported in 2025. Pfizer maintained its adjusted earnings guidance of $2.80 to $3 per share.
The company reduced its combined annual revenue forecast for its Covid vaccine and Paxlovid antiviral treatment to $4 billion from approximately $5 billion. The change reflects the continued decline in Covid-related product sales.
Pfizer also expanded its cost-reduction plans by $2.5 billion across two programs, with the additional savings scheduled to begin in 2027 and continue through 2029.
About $1.5 billion of the new reductions will come from the second phase of a multi-year initiative involving changes to Pfizer’s product portfolio, manufacturing network and operating structure. The first phase of that initiative remains on schedule to produce $1.5 billion in savings by the end of 2027. A separate program is expected to generate another $1 billion in savings between 2027 and 2029. That amount is in addition to $5.7 billion in previously announced reductions that Pfizer expects to achieve by the end of 2026.
Pfizer is directing longer-term investment toward its drug pipeline as sales of Covid products and older medicines decline. Those investments include its $10 billion acquisition of obesity biotechnology company Metsera.
The company is also preparing to release clinical data involving a combination regimen that includes its GLP-1 injection and an amylin asset.
About Pfizer
Pfizer Inc. (NYSE: PFE) was founded in 1849 and is headquartered in New York. The company develops and manufactures prescription medicines and vaccines for patients worldwide.
At the time of publishing, Stocks.News holds positions in Pfizer as mentioned in the article.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned throughout the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
